Logo image of ARWR

ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Fundamental Analysis

NASDAQ:ARWR - Nasdaq - US04280A1007 - Common Stock - Currency: USD

16.065  +0.15 (+0.91%)

Fundamental Rating

3

ARWR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. ARWR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARWR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ARWR had negative earnings in the past year.
In the past year ARWR had a positive cash flow from operations.
ARWR had negative earnings in each of the past 5 years.
ARWR had negative operating cash flow in 4 of the past 5 years.
ARWR Yearly Net Income VS EBIT VS OCF VS FCFARWR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

ARWR's Return On Assets of -9.15% is amongst the best of the industry. ARWR outperforms 84.71% of its industry peers.
Looking at the Return On Equity, with a value of -21.07%, ARWR belongs to the top of the industry, outperforming 84.71% of the companies in the same industry.
Industry RankSector Rank
ROA -9.15%
ROE -21.07%
ROIC N/A
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ARWR Yearly ROA, ROE, ROICARWR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

ARWR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARWR Yearly Profit, Operating, Gross MarginsARWR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

ARWR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARWR has been increased compared to 1 year ago.
Compared to 5 years ago, ARWR has more shares outstanding
The debt/assets ratio for ARWR is higher compared to a year ago.
ARWR Yearly Shares OutstandingARWR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ARWR Yearly Total Debt VS Total AssetsARWR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ARWR has an Altman-Z score of 1.01. This is a bad value and indicates that ARWR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.01, ARWR is in the better half of the industry, outperforming 65.47% of the companies in the same industry.
The Debt to FCF ratio of ARWR is 28.55, which is on the high side as it means it would take ARWR, 28.55 years of fcf income to pay off all of its debts.
ARWR's Debt to FCF ratio of 28.55 is amongst the best of the industry. ARWR outperforms 91.01% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ARWR is not too dependend on debt financing.
ARWR has a Debt to Equity ratio of 0.31. This is in the lower half of the industry: ARWR underperforms 72.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 28.55
Altman-Z 1.01
ROIC/WACCN/A
WACC9.56%
ARWR Yearly LT Debt VS Equity VS FCFARWR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

2.3 Liquidity

A Current Ratio of 5.15 indicates that ARWR has no problem at all paying its short term obligations.
ARWR has a Current ratio (5.15) which is comparable to the rest of the industry.
ARWR has a Quick Ratio of 5.15. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
ARWR has a Quick ratio (5.15) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.15
Quick Ratio 5.15
ARWR Yearly Current Assets VS Current LiabilitesARWR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.22% over the past year.
ARWR shows a strong growth in Revenue. In the last year, the Revenue has grown by 1438.05%.
The Revenue for ARWR have been decreasing by -53.80% on average. This is quite bad
EPS 1Y (TTM)67.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%369.61%
Revenue 1Y (TTM)1438.05%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%N/A

3.2 Future

ARWR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.82% yearly.
Based on estimates for the next years, ARWR will show a very strong growth in Revenue. The Revenue will grow by 61.63% on average per year.
EPS Next Y100.84%
EPS Next 2Y14.69%
EPS Next 3Y8.17%
EPS Next 5Y14.82%
Revenue Next Year944.66%
Revenue Next 2Y104.32%
Revenue Next 3Y69.66%
Revenue Next 5Y61.63%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARWR Yearly Revenue VS EstimatesARWR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ARWR Yearly EPS VS EstimatesARWR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ARWR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARWR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARWR Price Earnings VS Forward Price EarningsARWR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARWR indicates a rather cheap valuation: ARWR is cheaper than 91.01% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 231.2
EV/EBITDA N/A
ARWR Per share dataARWR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.69%
EPS Next 3Y8.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARWR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (7/24/2025, 9:52:03 AM)

16.065

+0.15 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners76.99%
Inst Owner Change0%
Ins Owners3.82%
Ins Owner Change2.57%
Market Cap2.22B
Analysts78.1
Price Target44.88 (179.37%)
Short Float %10.5%
Short Ratio7.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)625.15%
Min EPS beat(2)-211.36%
Max EPS beat(2)1461.66%
EPS beat(4)1
Avg EPS beat(4)269.22%
Min EPS beat(4)-211.36%
Max EPS beat(4)1461.66%
EPS beat(8)1
Avg EPS beat(8)50.38%
EPS beat(12)2
Avg EPS beat(12)-2.29%
EPS beat(16)3
Avg EPS beat(16)1.62%
Revenue beat(2)1
Avg Revenue beat(2)791.73%
Min Revenue beat(2)-96.63%
Max Revenue beat(2)1680.09%
Revenue beat(4)1
Avg Revenue beat(4)345.87%
Min Revenue beat(4)-100%
Max Revenue beat(4)1680.09%
Revenue beat(8)1
Avg Revenue beat(8)132.24%
Revenue beat(12)2
Avg Revenue beat(12)94.15%
Revenue beat(16)4
Avg Revenue beat(16)69.08%
PT rev (1m)-1.12%
PT rev (3m)-1.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.03%
EPS NY rev (1m)0%
EPS NY rev (3m)101.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-47.98%
Revenue NY rev (1m)2.09%
Revenue NY rev (3m)401.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.07
P/FCF 231.2
P/OCF 36.28
P/B 3.25
P/tB 3.28
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-3.43
Fwd EYN/A
FCF(TTM)0.07
FCFY0.43%
OCF(TTM)0.44
OCFY2.76%
SpS3.95
BVpS4.95
TBVpS4.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.15%
ROE -21.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 1.76%
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 28.55
Debt/EBITDA N/A
Cap/Depr 244.02%
Cap/Sales 9.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.15
Quick Ratio 5.15
Altman-Z 1.01
F-Score5
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)894.03%
Cap/Depr(5y)633.96%
Cap/Sales(3y)1359.68%
Cap/Sales(5y)821.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%369.61%
EPS Next Y100.84%
EPS Next 2Y14.69%
EPS Next 3Y8.17%
EPS Next 5Y14.82%
Revenue 1Y (TTM)1438.05%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%N/A
Revenue Next Year944.66%
Revenue Next 2Y104.32%
Revenue Next 3Y69.66%
Revenue Next 5Y61.63%
EBIT growth 1Y74.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.15%
EBIT Next 3Y-0.59%
EBIT Next 5Y11.01%
FCF growth 1Y102.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y124.99%
OCF growth 3YN/A
OCF growth 5YN/A